Literature DB >> 21417821

Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia.

Ulas Darda Bayraktar, Gelenis Calzadilla Domingo, Jessica Schmit, Denise Pereira.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21417821     DOI： 10.3109/10428194.2010.551570

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  5 in total

Review 1.  New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.

Authors:  Steven D Gore
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome.

Authors:  Takayuki Ishikawa
Journal:  Int J Clin Oncol       Date:  2013-12-20       Impact factor: 3.402

Review 3.  Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.

Authors:  Amer M Zeidan; Mohamed A Kharfan-Dabaja; Rami S Komrokji
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

Review 4.  Current therapy of myelodysplastic syndromes.

Authors:  Amer M Zeidan; Yuliya Linhares; Steven D Gore
Journal:  Blood Rev       Date:  2013-07-27       Impact factor: 8.250

5.  Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study.

Authors:  Roland B Walter; Bruno C Medeiros; Kelda M Gardner; Kaysey F Orlowski; Leonel Gallegos; Bart L Scott; Paul C Hendrie; Elihu H Estey
Journal:  Haematologica       Date:  2013-10-18       Impact factor: 9.941
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.